Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial.
Polgár C, Ott OJ, Hildebrandt G, Kauer-Dorner D, Knauerhase H, Major T, Lyczek J, Guinot JL, Dunst J, Miguelez CG, Slampa P, Allgäuer M, Lössl K, Polat B, Kovács G, Fischedick AR, Fietkau R, Resch A, Kulik A, Arribas L, Niehoff P, Guedea F, Schlamann A, Pötter R, Gall C, Uter W, Strnad V; Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Polgár C, et al. Among authors: allgauer m. Lancet Oncol. 2017 Feb;18(2):259-268. doi: 10.1016/S1470-2045(17)30011-6. Epub 2017 Jan 14. Lancet Oncol. 2017. PMID: 28094198 Clinical Trial.
COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy.
Pixberg C, Zapatka M, Hlevnjak M, Benedetto S, Suppelna JP, Heil J, Smetanay K, Michel L, Fremd C, Körber V, Rübsam M, Buschhorn L, Heublein S, Schäfgen B, Golatta M, Gomez C, von Au A, Wallwiener M, Wolf S, Dikow N, Schaaf C, Gutjahr E, Allgäuer M, Stenzinger A, Pfütze K, Kirsten R, Hübschmann D, Sinn HP, Jäger D, Trumpp A, Schlenk R, Höfer T, Thewes V, Schneeweiss A, Lichter P. Pixberg C, et al. Among authors: allgauer m. ESMO Open. 2022 Dec;7(6):100637. doi: 10.1016/j.esmoop.2022.100637. Epub 2022 Nov 21. ESMO Open. 2022. PMID: 36423362 Free PMC article. Clinical Trial.
Spatial profiling of the microenvironment reveals low intratumoral heterogeneity and STK11-associated immune evasion in therapy-naïve lung adenocarcinomas.
Goldschmid H, Kluck K, Ball M, Kirchner M, Allgäuer M, Winter H, Herth F, Heußel CP, Pullamsetti SS, Savai R, Yong TTK, Schirmacher P, Peters S, Thomas M, Christopoulos P, Budczies J, Stenzinger A, Kazdal D. Goldschmid H, et al. Among authors: allgauer m. Lung Cancer. 2023 Jun;180:107212. doi: 10.1016/j.lungcan.2023.107212. Epub 2023 Apr 23. Lung Cancer. 2023. PMID: 37141769
Leveraging Off-Target Reads in Panel Sequencing for Homologous Recombination Repair Deficiency Screening in Tumor.
Ball M, Ourailidis I, Kluck K, Menzel M, Kirchner M, Allgäuer M, Tay TKY, Schnecko F, Volckmar AL, Goldschmid H, Neuman O, Fröhling S, Schirmacher P, Budczies J, Stenzinger A, Kazdal D. Ball M, et al. Among authors: allgauer m. J Mol Diagn. 2024 Jun;26(6):479-486. doi: 10.1016/j.jmoldx.2024.02.008. Epub 2024 Mar 22. J Mol Diagn. 2024. PMID: 38522840 Free article.
First proficiency testing for NGS-based and combined NGS- and FISH-based detection of FGFR2 fusions in intrahepatic cholangiocarcinoma.
Neumann O, Lehmann U, Bartels S, Pfarr N, Albrecht T, Ilm K, Christmann J, Volckmar AL, Goldschmid H, Kirchner M, Allgäuer M, Walker M, Kreipe H, Tannapfel A, Weichert W, Schirmacher P, Kazdal D, Stenzinger A. Neumann O, et al. Among authors: allgauer m. J Pathol Clin Res. 2023 Mar;9(2):100-107. doi: 10.1002/cjp2.308. Epub 2023 Jan 12. J Pathol Clin Res. 2023. PMID: 36635225 Free PMC article.
Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR-mutated lung cancer treated with the first-/second-generation tyrosine kinase inhibitors.
Menzel M, Kirchner M, Kluck K, Ball M, Beck S, Allgäuer M, Assmann C, Schnorbach J, Volckmar AL, Tay TKY, Goldschmid H, Tan DS, Thomas M, Kazdal D, Budczies J, Stenzinger A, Christopoulos P. Menzel M, et al. Among authors: allgauer m. J Pathol Clin Res. 2024 Mar;10(2):e354. doi: 10.1002/cjp2.354. J Pathol Clin Res. 2024. PMID: 38284983 Free PMC article.
The pregnancy-associated protein glycodelin as a potential sex-specific target for resistance to immunotherapy in non-small cell lung cancer.
Richtmann S, Marwitz S, Muley T, Koistinen H, Christopoulos P, Thomas M, Kazdal D, Allgäuer M, Winter H, Goldmann T, Meister M, Klingmüller U, Schneider MA. Richtmann S, et al. Among authors: allgauer m. Transl Res. 2024 Oct;272:177-189. doi: 10.1016/j.trsl.2024.02.007. Epub 2024 Mar 13. Transl Res. 2024. PMID: 38490536 Free article.
First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations.
Blasi M, Kuon J, Lüders H, Misch D, Kauffmann-Guerrero D, Hilbrandt M, Kazdal D, Falkenstern-Ge RF, Hackanson B, Dintner S, Faehling M, Kirchner M, Volckmar AL, Kopp HG, Allgäuer M, Grohé C, Tufman A, Reck M, Frost N, Stenzinger A, Thomas M, Christopoulos P. Blasi M, et al. Among authors: allgauer m. Eur J Cancer. 2024 Mar;199:113556. doi: 10.1016/j.ejca.2024.113556. Epub 2024 Jan 17. Eur J Cancer. 2024. PMID: 38271745 Free article.
Analysis of rare fusions in NSCLC: Genomic architecture and clinical implications.
Seker-Cin H, Tay TKY, Kazdal D, Kluck K, Ball M, Neumann O, Winter H, Herth F, Heußel CP, Savai R, Schirmacher P, Thomas M, Budczies J, Allgäuer M, Christopoulos P, Stenzinger A, Volckmar AL. Seker-Cin H, et al. Among authors: allgauer m. Lung Cancer. 2023 Oct;184:107317. doi: 10.1016/j.lungcan.2023.107317. Epub 2023 Jul 27. Lung Cancer. 2023. PMID: 37586177
96 results